Chemomab Therapeutics Ltd. (CMMB)
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$9.0M
- Total assets
- $13.8M
- Market cap
- $10.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $28.5M
- Income tax
- -$534.0K
- Net income
- -$27.6M
- EPS (basic)
- $0.12
- EPS (diluted)
- $0.12
Balance sheet
- Total assets
- $43.1M
- Current assets
- $41.7M
- Total liabilities
- $6.8M
- Current liabilities
- $6.7M
- Shareholders’ equity
- $36.2M
Cash flow
- Operating cash flow
- -$20.4M
- Investing cash flow
- $19.5M
- Financing cash flow
- -$808.0K
- Net cash flow
- -$1.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $10.0M
- P/E ratio
- 11.2
- EPS (diluted)
- $0.121
- Shares outstanding
- 9.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 17, 2021
Chemomab Therapeutics Ltd. (CMMB) Stock Price
- Reported a net loss of $9.0M.
- Trading 72% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 11.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Chemomab Therapeutics Ltd..
Write a review
News about Chemomab Therapeutics Ltd.
News & sentiment via Polygon.io
Chemomab Therapeutics Ltd.: frequently asked questions
Is Chemomab Therapeutics Ltd. an American company?
Chemomab Therapeutics Ltd. is a US-based company headquartered in Tel Aviv, L3, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Chemomab Therapeutics Ltd. headquartered?
Chemomab Therapeutics Ltd. is headquartered in Tel Aviv, L3, United States.
Is Chemomab Therapeutics Ltd. publicly traded?
Yes — Chemomab Therapeutics Ltd. is a publicly traded company. Its stock trades under the ticker symbol CMMB on the NASDAQ.
What does Chemomab Therapeutics Ltd. do?
Chemomab Therapeutics Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.
